These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6617 related articles for article (PubMed ID: 1878892)

  • 1. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2.
    Weidmann E; Bergmann L; Hechler P; Mitrou PS
    Cancer Immunol Immunother; 1991; 33(6):398-402. PubMed ID: 1878892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
    Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures.
    Fuchshuber PR; Lotzová E
    Lymphokine Cytokine Res; 1992 Oct; 11(5):271-6. PubMed ID: 1281676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors.
    Kalwak K; Ussowicz M; Gorczyńska E; Turkiewicz D; Toporski J; Dobaczewski G; Latos-Grazyńska E; Ryczan R; Noworolska-Sauren D; Chybicka A
    J Interferon Cytokine Res; 2003 Apr; 23(4):173-81. PubMed ID: 12856329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin-2 and interferon alpha.
    Prigione I; Facchetti P; Lanino E; Garaventa A; Pistoia V
    Cancer Immunol Immunother; 1993 Jul; 37(1):40-6. PubMed ID: 8513451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
    Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
    Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy.
    Murta EF; de Andrade JM; Falcão RP; Bighetti S
    Tumori; 2000; 86(5):403-7. PubMed ID: 11130570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
    Parrado A; Casares S; Rodríguez-Fernández JM
    Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of cryopreservation on activity and surface markers of lymphokine-activated killer cells.
    Letellier C; Rameliarison L; Fizet D; Ferrer AM; Vezon G
    Vox Sang; 1991; 61(2):90-5. PubMed ID: 1763504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.
    Lotzová E; Savary CA; Schachner JR; Huh JO; McCredie K
    Am J Hematol; 1991 Jun; 37(2):88-99. PubMed ID: 2069169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
    Zupo S; Azzoni L; Massara R; D'Amato A; Perussia B; Ferrarini M
    J Clin Immunol; 1993 May; 13(3):228-36. PubMed ID: 7686565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repopulation of circulating T, B and NK lymphocytes following bone marrow and blood stem cell transplantation.
    Parrado A; Casares S; Prieto J; Carmona M; Vaquero A; Rodríguez-Fernández JM
    Hematol Cell Ther; 1997 Dec; 39(6):301-6. PubMed ID: 9497889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
    Yoneda K; Yamamoto T; Ueta E; Osaki T
    J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
    Gaddy J; Broxmeyer HE
    Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 331.